IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v24y2006i12p1221-1232.html
   My bibliography  Save this article

Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis

Author

Listed:
  • James Spalding
  • Joel Hay

Abstract

While these ICERs cannot be used to directly compare one biological agent with another since there are no comparative trials, they do provide a valid comparison versus methotrexate as first-line agents. Depending where the cost-effectiveness threshold is drawn (i.e. whether it is considered to be $US50 000 or $US100 000 per QALY), etanercept and adalimumab may be considered relatively cost-effective first-line treatments for RA compared with methotrexate monotherapy. Copyright Adis Data Information BV 2006

Suggested Citation

  • James Spalding & Joel Hay, 2006. "Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 24(12), pages 1221-1232, December.
    • Handle: RePEc:spr:pharme:v:24:y:2006:i:12:p:1221-1232
    DOI: 10.2165/00019053-200624120-00006
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200624120-00006
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200624120-00006?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Hussain Abdulrahman Al-Omar & Hadeel Magdy Sherif & Ahmed Yaccob Mayet, 2019. "Vaccination status of patients using anti-TNF therapy and the physicians’ behavior shaping the phenomenon: Mixed-methods approach," PLOS ONE, Public Library of Science, vol. 14(10), pages 1-15, October.
    2. Christine Nguyen & Mark Bounthavong & Margaret Mendes & Melissa Christopher & Josephine Tran & Rashid Kazerooni & Anthony Morreale, 2012. "Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 30(7), pages 575-593, July.
    3. Stefan Scholz & Thomas Mittendorf, 2014. "Modeling rheumatoid arthritis using different techniques - a review of model construction and results," Health Economics Review, Springer, vol. 4(1), pages 1-16, December.
    4. Sandmann, Frank G. & Franken, Margreet G. & Steenhoek, Adri & Koopmanschap, Marc A., 2013. "Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time," Health Policy, Elsevier, vol. 112(3), pages 285-296.
    5. Evo Alemao & Maiwenn J Al & Annelies A Boonen & Matthew D Stevenson & Suzanne M M Verstappen & Kaleb Michaud & Michael E Weinblatt & Maureen P M H Rutten-van Mölken, 2018. "Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-18, October.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:24:y:2006:i:12:p:1221-1232. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.